Pharmaceutical company Devonian Health Group Inc (TSXV: GSD) (OTCQB: DVHGF) announced on Wednesday that it has filed a new patent application for the use of Thykamine as an antifibrotic agent.

Thykamine, developed through the company's SUPREX platform, has demonstrated anti-inflammatory, antioxidative and immunomodulatory properties in clinical studies targeting conditions such as ulcerative colitis and atopic dermatitis.

Fibrosis, a key factor in chronic disease progression affecting organs including the skin, heart, lungs and liver, leads to structural damage and increased morbidity. Thykamine has the potential to address this unmet medical need by preventing excessive fibrous tissue accumulation.

Devonian specialises in developing prescription drugs for inflammatory autoimmune diseases and also operates Altius Healthcare Group L.P., its pharmaceutical commercialisation subsidiary in Canada. Headquartered in Québec, Devonian owns an advanced extraction facility ensuring full traceability in drug development.